Developer docs
API playgroundTry for free, no card

Search company profiles

FibroGen China

Full company profile

uuid000h7nm

Namestring
FibroGen China
Legal namestring
Kyntra Bio, Inc.
Websiteurl
fibrogen.com
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Kyntra Bio (formerly FibroGen, rebranded January 2026) is a clinical-stage biopharmaceutical company headquartered in San Francisco that develops therapeutics for oncology and rare-disease anemia. The company's pipeline is anchored by two programs: roxadustat, an oral small-molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China, Europe, Japan and numerous other markets for anemia in chronic kidney disease and in Phase 3 development for anemia in lower-risk myelodysplastic syndromes (LR-MDS); and FG-3246, a potential first-in-class fully human antibody-drug conjugate targeting CD46, comprising the anti-CD46 antibody YS-5 linked to MMAE, currently in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). A companion CD46-targeted PET imaging agent, FG-3180, is being co-developed to identify CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

The business model is pre-commercial: Kyntra Bio has no approved products in its current pipeline and generates no product revenue. Commercialization is executed through partners — Astellas Pharma holds roxadustat rights across Japan, Europe, the Middle East, Russia/CIS, Turkey, South Africa and select other territories under a partnership established in 2004, while FG-3246 was in-licensed from Fortis Therapeutics in May 2023. Kyntra Bio retains roxadustat rights in the U.S., Canada, Mexico and all non-partnered markets. In November 2025, the company divested its China operations (FibroGen China) to AstraZeneca for approximately $220 million, a transaction that funded a strategic refocus and extended cash runway into 2028. The company trades on Nasdaq as KYNB following a 1-for-25 reverse stock split executed in June 2025.

Kyntra Bio serves patient populations with significant unmet medical need: approximately 60,000 U.S. adults with LR-MDS (of whom roughly 85% develop anemia, and fewer than 50% achieve transfusion independence on current therapy), and approximately 65,000 U.S. drug-treatable mCRPC cases annually with 5-year survival near 30%. The company employs 101-250 staff, leans on investigator-sponsored and academic collaborations (including with UCSF), and conducts its go-to-market through medical/scientific conferences, ClinicalTrials.gov disclosures, investor relations, and corporate communications rather than direct sales infrastructure.

Short descriptiontext

Kyntra Bio (formerly FibroGen China) is a clinical-stage biopharmaceutical company developing roxadustat (oral HIF-PH inhibitor) for LR-MDS anemia and FG-3246, a CD46-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, anemia treatment, antibody-drug conjugate, HIF-PH inhibitor, biopharmaceutical development
Industry2 codes
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Potential Commercialization
TypeOne Time License
Description

Pre-revenue biotech company. In Q3 2025, FibroGen sold FibroGen China to AstraZeneca for approximately $220 million. The company is developing roxadustat (approved in China, Europe, Japan for CKD anemia) and FG-3246 (Phase 2 for mCRPC) with no approved products yet in its current pipeline.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FibroGen China operated as the China-based pharmaceutical subsidiary of FibroGen, focused on developing and commercializing roxadustat (an oral HIF-PH inhibitor for chronic kidney disease anemia) in the Chinese market. Following the Q3 2025 sale to AstraZeneca for ~$220 million, FibroGen China is no longer part of the parent (now rebranded as Kyntra Bio), which continues to advance the FG-3246 CD46-targeted ADC and roxadustat pipeline for oncology and rare disease indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Approximately 60,000 adults diagnosed with LR-MDS in the U.S.
+4 more records
Product overview1 text field

Kyntra Bio (formerly FibroGen) is a biopharmaceutical company pioneering oncology and rare disease therapies. The company's product portfolio centers on two key programs: Roxadustat, an oral HIF-PH inhibitor approved globally for anemia in chronic kidney disease and in Phase 3 development for LR-MDS; and the FG-3246/FG-3180 program featuring a CD46-targeted ADC (FG-3246) for mCRPC paired with a companion PET imaging agent (FG-3180) for patient selection. The company operates through strategic partnerships with Astellas Pharma (for roxadustat commercialization in Europe, Japan, and other territories) and Fortis Therapeutics (for FG-3246).

Product and service3 records
1Roxadustat
CategoryBiopharmaceutical / Nephrology Therapeutic
Description

An oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin levels. Approved in China, Europe, Japan and numerous other countries for anemia in chronic kidney disease patients. Currently in Phase 3 development for lower-risk myelodysplastic syndromes (LR-MDS) anemia.

2FG-3246
CategoryBiopharmaceutical / Oncology Therapeutic
Description

A potential first-in-class, fully human antibody-drug conjugate (ADC) targeting CD46, comprised of anti-CD46 antibody YS-5 linked to monomethyl auristatin E (MMAE). Currently in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC) with potential for additional trials targeting other CD46-expressing cancers.

3FG-3180
CategoryBiopharmaceutical / Companion Diagnostic
Description

A CD46-targeted PET imaging agent that uses the same antibody backbone as FG-3246. Being evaluated as an exploratory sub-study to detect CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In May 2023, Kyntra Bio entered into an exclusive license with Fortis Therapeutics for FOR46 (FG-3246), a potential first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer. Kyntra Bio initiated Phase 2 trial for FG-3246 in mCRPC with potential for additional trials targeting other CD46-expressing cancers. Also studying FG-3180, a PET-based biomarker to assess correlation between CD46 expression and FG-3246 response.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Longstanding strategic partnership established in 2004 focused on development and commercialization of roxadustat for anemia associated with chronic kidney disease. Collaboration grants Astellas rights to develop and market roxadustat in Japan, Europe, Middle East, Russia, Commonwealth of Independent States, Turkey, South Africa, and select other territories. Roxadustat is approved in multiple regions under this partnership. Kyntra Bio retains rights in U.S., Canada, Mexico, and all markets not held by Astellas (excluding China and South Korea).

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trials collaboration. Phase 1b/2 Study of FG-3246 (FOR46) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer conducted in partnership with UCSF. Kyntra Bio maintains active clinical trial programs with academic research institutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Co-markets enzalutamide with Astellas and has a broad oncology pipeline including ADCs and prostate cancer therapies, overlapping with Kyntra Bio's target indications.

TypeBroad incumbent
Description

Acquired FibroGen China for ~$220M and has a major oncology and rare-disease franchise, including ADC platforms (Enhertu) that compete conceptually with FG-3246.

TypeDirect peer
Description

Develops vadadustat, another oral HIF-PH inhibitor for anemia in chronic kidney disease — a direct competitor to roxadustat in the same mechanism and indications.

TypeEmerging player
Description

Clinical-stage oncology company developing antibody-based therapeutics including ADCs, with comparable technology and pre-commercial profile to Kyntra Bio's FG-3246 program.

TypeDirect peer
Description

Markets darolutamide (Nubeqa) for mCRPC, a direct competitor to FG-3246, and is one of the established players in the prostate cancer treatment landscape Kyntra Bio targets.

TypeBroad incumbent
Description

Global leader in ADC technology (Enhertu, Datroway), representing the standard against which next-generation ADCs like FG-3246 are benchmarked in oncology development.

TypeEmerging player
Description

Clinical-stage biopharma focused on rare disease and oncology, with a similar pre-commercial, partnership-driven model and a comparable mid-stage pipeline posture.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Major oncology player with ADCs and mCRPC therapies (e.g., OPDIVO combinations), and a CDK/mDS-adjacent hematology franchise overlapping with Kyntra Bio's LR-MDS anemia opportunity.

TypeDirect peer
Description

Strategic partner on roxadustat and developer of enzalutamide (Xtandi), one of the leading therapies for metastatic castration-resistant prostate cancer — directly competing with FG-3246 in mCRPC.

TypeBroad incumbent
Description

Develops apalutamide (Erleada) for mCRPC and operates a deep oncology and hematology portfolio, making it a benchmark incumbent in the prostate cancer space Kyntra Bio is pursuing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FibroGen China

Biopharmaceuticalsfibrogen.com

Kyntra Bio (formerly FibroGen China) is a clinical-stage biopharmaceutical company developing roxadustat (oral HIF-PH inhibitor) for LR-MDS anemia and FG-3246, a CD46-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer.

What FibroGen China does

Kyntra Bio (formerly FibroGen, rebranded January 2026) is a clinical-stage biopharmaceutical company headquartered in San Francisco that develops therapeutics for oncology and rare-disease anemia. The company's pipeline is anchored by two programs: roxadustat, an oral small-molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China, Europe, Japan and numerous other markets for anemia in chronic kidney disease and in Phase 3 development for anemia in lower-risk myelodysplastic syndromes (LR-MDS); and FG-3246, a potential first-in-class fully human antibody-drug conjugate targeting CD46, comprising the anti-CD46 antibody YS-5 linked to MMAE, currently in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). A companion CD46-targeted PET imaging agent, FG-3180, is being co-developed to identify CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

The business model is pre-commercial: Kyntra Bio has no approved products in its current pipeline and generates no product revenue. Commercialization is executed through partners — Astellas Pharma holds roxadustat rights across Japan, Europe, the Middle East, Russia/CIS, Turkey, South Africa and select other territories under a partnership established in 2004, while FG-3246 was in-licensed from Fortis Therapeutics in May 2023. Kyntra Bio retains roxadustat rights in the U.S., Canada, Mexico and all non-partnered markets. In November 2025, the company divested its China operations (FibroGen China) to AstraZeneca for approximately $220 million, a transaction that funded a strategic refocus and extended cash runway into 2028. The company trades on Nasdaq as KYNB following a 1-for-25 reverse stock split executed in June 2025.

Kyntra Bio serves patient populations with significant unmet medical need: approximately 60,000 U.S. adults with LR-MDS (of whom roughly 85% develop anemia, and fewer than 50% achieve transfusion independence on current therapy), and approximately 65,000 U.S. drug-treatable mCRPC cases annually with 5-year survival near 30%. The company employs 101-250 staff, leans on investigator-sponsored and academic collaborations (including with UCSF), and conducts its go-to-market through medical/scientific conferences, ClinicalTrials.gov disclosures, investor relations, and corporate communications rather than direct sales infrastructure.

FibroGen China firmographics

Firmographics
Name
FibroGen China
Legal name
Kyntra Bio, Inc.
Website
https://fibrogen.com
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
Kyntra Bio (formerly FibroGen China) is a clinical-stage biopharmaceutical company developing roxadustat (oral HIF-PH inhibitor) for LR-MDS anemia and FG-3246, a CD46-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer.
Ownership category
akta.pro rank

FibroGen China industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Anemia treatment
  • Antibody-drug conjugate
  • HIF-PH inhibitor
  • Biopharmaceutical development

Where FibroGen China is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FibroGen China business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Potential Commercialization: Pre-revenue biotech company. In Q3 2025, FibroGen sold FibroGen China to AstraZeneca for approximately $220 million. The company is developing roxadustat (approved in China, Europe, Japan for CKD anemia) and FG-3246 (Phase 2 for mCRPC) with no approved products yet in its current pipeline.

Go-to-market motion1 record

Marketing channels4 records

FibroGen China product offering

Product offering

Core offering

FibroGen China operated as the China-based pharmaceutical subsidiary of FibroGen, focused on developing and commercializing roxadustat (an oral HIF-PH inhibitor for chronic kidney disease anemia) in the Chinese market. Following the Q3 2025 sale to AstraZeneca for ~$220 million, FibroGen China is no longer part of the parent (now rebranded as Kyntra Bio), which continues to advance the FG-3246 CD46-targeted ADC and roxadustat pipeline for oncology and rare disease indications.

Product overview

Kyntra Bio (formerly FibroGen) is a biopharmaceutical company pioneering oncology and rare disease therapies. The company's product portfolio centers on two key programs: Roxadustat, an oral HIF-PH inhibitor approved globally for anemia in chronic kidney disease and in Phase 3 development for LR-MDS; and the FG-3246/FG-3180 program featuring a CD46-targeted ADC (FG-3246) for mCRPC paired with a companion PET imaging agent (FG-3180) for patient selection. The company operates through strategic partnerships with Astellas Pharma (for roxadustat commercialization in Europe, Japan, and other territories) and Fortis Therapeutics (for FG-3246).

Differentiator

Problem solved

Functional benefit

Products and services

  • Roxadustat An oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin levels. Approved in China, Europe, Japan and numerous other countries for anemia in chronic kidney disease patients. Currently in Phase 3 development for lower-risk myelodysplastic syndromes (LR-MDS) anemia.
  • FG-3246 A potential first-in-class, fully human antibody-drug conjugate (ADC) targeting CD46, comprised of anti-CD46 antibody YS-5 linked to monomethyl auristatin E (MMAE). Currently in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC) with potential for additional trials targeting other CD46-expressing cancers.
  • FG-3180 A CD46-targeted PET imaging agent that uses the same antibody backbone as FG-3246. Being evaluated as an exploratory sub-study to detect CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

Quantifiable outcome

  • Approximately 60,000 adults diagnosed with LR-MDS in the U.S.
  • +4 more outcomes

Companies that use FibroGen China

Customer profile

Segments2 records

Ideal customer profiles2 records

FibroGen China technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

FibroGen China partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Fortis TherapeuticscoreStrategic or Co-development PartnerIn May 2023, Kyntra Bio entered into an exclusive license with Fortis Therapeutics for FOR46 (FG-3246), a potential first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer. Kyntra Bio initiated Phase 2 trial for FG-3246 in mCRPC with potential for additional trials targeting other CD46-expressing cancers. Also studying FG-3180, a PET-based biomarker to assess correlation between CD46 expression and FG-3246 response.
  • Astellas PharmacoreStrategic or Co-development PartnerLongstanding strategic partnership established in 2004 focused on development and commercialization of roxadustat for anemia associated with chronic kidney disease. Collaboration grants Astellas rights to develop and market roxadustat in Japan, Europe, Middle East, Russia, Commonwealth of Independent States, Turkey, South Africa, and select other territories. Roxadustat is approved in multiple regions under this partnership. Kyntra Bio retains rights in U.S., Canada, Mexico, and all markets not held by Astellas (excluding China and South Korea).
  • UCSF (University of California, San Francisco)supportingStrategic or Co-development PartnerClinical trials collaboration. Phase 1b/2 Study of FG-3246 (FOR46) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer conducted in partnership with UCSF. Kyntra Bio maintains active clinical trial programs with academic research institutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

FibroGen China competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Co-markets enzalutamide with Astellas and has a broad oncology pipeline including ADCs and prostate cancer therapies, overlapping with Kyntra Bio's target indications.
  • AstraZeneca: Acquired FibroGen China for ~$220M and has a major oncology and rare-disease franchise, including ADC platforms (Enhertu) that compete conceptually with FG-3246.
  • Daiichi Sankyo: Global leader in ADC technology (Enhertu, Datroway), representing the standard against which next-generation ADCs like FG-3246 are benchmarked in oncology development.
  • Bristol Myers Squibb: Major oncology player with ADCs and mCRPC therapies (e.g., OPDIVO combinations), and a CDK/mDS-adjacent hematology franchise overlapping with Kyntra Bio's LR-MDS anemia opportunity.
  • Johnson & Johnson (Janssen): Develops apalutamide (Erleada) for mCRPC and operates a deep oncology and hematology portfolio, making it a benchmark incumbent in the prostate cancer space Kyntra Bio is pursuing.

Direct peers

  • Akebia Therapeutics: Develops vadadustat, another oral HIF-PH inhibitor for anemia in chronic kidney disease — a direct competitor to roxadustat in the same mechanism and indications.
  • Bayer: Markets darolutamide (Nubeqa) for mCRPC, a direct competitor to FG-3246, and is one of the established players in the prostate cancer treatment landscape Kyntra Bio targets.
  • Astellas Pharma: Strategic partner on roxadustat and developer of enzalutamide (Xtandi), one of the leading therapies for metastatic castration-resistant prostate cancer — directly competing with FG-3246 in mCRPC.

Emerging players

  • MacroGenics: Clinical-stage oncology company developing antibody-based therapeutics including ADCs, with comparable technology and pre-commercial profile to Kyntra Bio's FG-3246 program.
  • Mereo BioPharma: Clinical-stage biopharma focused on rare disease and oncology, with a similar pre-commercial, partnership-driven model and a comparable mid-stage pipeline posture.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

FibroGen China social profiles

Digital presence

FibroGen China financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FibroGen China leadership team

Management profile

Number of profiles

FibroGen China subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

FibroGen China funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FibroGen China M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FibroGen China

What does FibroGen China do?

FibroGen China operated as the China-based pharmaceutical subsidiary of FibroGen, focused on developing and commercializing roxadustat (an oral HIF-PH inhibitor for chronic kidney disease anemia) in the Chinese market. Following the Q3 2025 sale to AstraZeneca for ~$220 million, FibroGen China is no longer part of the parent (now rebranded as Kyntra Bio), which continues to advance the FG-3246 CD46-targeted ADC and roxadustat pipeline for oncology and rare disease indications.

Is FibroGen China a public or private company?

FibroGen China is a public company. It is classified as corporate owned and is currently operating.

When was FibroGen China founded?

FibroGen China was founded in 1993. It employs 11 to 50 people.

Where is FibroGen China based?

FibroGen China is headquartered in San Francisco, United States, in the North America region.

How does FibroGen China make money?

One revenue line is on record: drug Development and Potential Commercialization.

Who are FibroGen China's main competitors?

Broad incumbents on record are Pfizer, AstraZeneca, Daiichi Sankyo, Bristol Myers Squibb and Johnson & Johnson (Janssen). Direct peers are Akebia Therapeutics, Bayer and Astellas Pharma. Emerging players are MacroGenics and Mereo BioPharma.

Does FibroGen China have an API?

No public API is recorded for FibroGen China.

What industry is FibroGen China in?

FibroGen China's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAM, Nephrology & Urology Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialDuchenne Muscular Dystrophy Market Set To Grow Substantially Through 2034, Delveinsight Projects Sarepta Therapeutics, Santhera Pharma, Reveragen Biopharma, Pfizer, Fibrogen, Capricor TherapeuticsThe Duchenne muscular dystrophy market was valued at approximately $2.15 billion in 2023 and is projected to grow substantially through 2034. The U.S. holds the largest market share at about $1.9 billion, with prevalence expected to rise. Multiple-stage pipeline products are anticipated to drive market dynamics.GlobeNewswireFibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateFibroGen reported Q1 2025 revenue of $2.7 million and a net loss of $16.8 million, with a China sale to AstraZeneca expected to close in Q3 2025 for about $185 million. The company plans to initiate a Phase 2 monotherapy trial of FG-3246 in Q3 2025 and expects topline results from a Phase 2 combination study in Q4 2025.GlobeNewswireFibroGen Reports Fourth Quarter and Full Year 2024 Financial ResultsFibroGen reported Q4 2024 revenue of $3.1 million and full-year revenue of $29.6 million, with a net loss of $8.7 million for the quarter and $153.1 million for the year. The company also announced the sale of FibroGen China to AstraZeneca for approximately $160 million, expected to close by mid-2025.ReutersAstraZeneca boosts China presence with FibroGen's anemia drug in $160 million dealAstraZeneca agreed to a $160 million licensing deal with FibroGen for its anemia drug Evrenzo in China. The deal, expected to close by mid-2025, will help FibroGen repay term loans and extend its cash runway through 2027. The drug is approved in China and over 40 other countries.GlobeNewswireFibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateFibroGen announced topline results from two late-stage pamrevlumab pancreatic cancer trials, both failing to meet overall survival endpoints. The company will terminate the pamrevlumab program, cut U.S. headcount by about 75%, and wind down obligations. The collaboration agreements with AstraZeneca and Astellas for roxadustat remain in place.Seeking AlphaFibroGen stock plunges 48% post-market on failed drug studies (NASDAQ:FGEN)FibroGen shares fell 48% post-market after the company cut its U.S. workforce by 75% due to failed clinical results for its pancreatic cancer drug pamrevlumab. The drug's Phase 2/3 study and Phase 3 LAPIS trial both missed their primary overall survival endpoint, leading FibroGen to end development and wind down obligations.GlobeNewswirePancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - FibroGen, OSE Immunotherapeutics, Panbela Therapeutics, Lokon Pharma, Helix Biopharma, Tvardi Therapeutics, BiDelveInsight's report projects the pancreatic cancer market in the 7MM to grow from $1.6 billion in 2020 to 2034, driven by rising cases and new therapies. The US saw about 64,000 incident cases in 2023, with growth expected due to aging populations and improved screening. Emerging drugs like pamrevlumab and SBP-101 are anticipated to reshape the market.Yahoo7 Penny Biotech Stocks to Triple Your InvestmentSeven penny biotech stocks—FibroGen, Nuvectis, Relmada, Anixa, Genenta, Affimed, and Lipocine—are profiled for potential investment returns. FibroGen reported Q1 revenue of $56 million and net losses of $32 million, while Lipocine posted $3.5 million net income. Analysts assign target prices ranging from $5 to $32, with consensus targets for several firms.Business Insider7 Penny Biotech Stocks to Triple Your InvestmentSeven penny biotech stocks are profiled, including FibroGen, Nuvectis, Relmada, Anixa, Genenta, Affimed, and Lipocine, with their development pipelines and analyst price targets. FibroGen reported Q1 revenue of $56 million, down from $36 million, and net losses fell to $32 million. Analysts see potential for triple returns, though failure risk remains.Nasdaq7 Penny Biotech Stocks to Triple Your InvestmentSeven penny biotech stocks are profiled, including FibroGen, Nuvectis Pharma, and Relmada Therapeutics, with their development pipelines and financials. FibroGen reported Q1 revenues near $56 million and net losses below $32 million, while Lipocine posted $3.5 million net income. Analysts assign target prices ranging from $5 to $33.